Experimental therapy of genetic arrhythmias: disease-specific pharmacology.
The integration between molecular biology and clinical practice requires the achievement of fundamental steps to link basic science to diagnosis and management of patients. In the last decade, the study of genetic bases of human diseases has achieved several milestones, and it is now possible to apply the knowledge that stems from the identification of the genetic substrate of diseases to clinical practice. The first step along the process of linking molecular biology to clinical medicine is the identification of the genetic bases of inherited diseases. After this important goal is achieved, it becomes possible to extend research to understand the functional impairments of mutant protein(s) and to link them to clinical manifestations (genotype-phenotype correlation). In genetically heterogeneous diseases, it may be possible to identify locus-specific risk stratification and management algorithms. Finally, the most ambitious step in the study of genetic disease is to discover a novel pharmacological therapy targeted at correcting the inborn defect (locus-specific therapy) or even to "cure" the DNA abnormality by replacing the defective gene with gene therapy. At present, this curative goal has been successful only for very few diseases. In the field of inherited arrhythmogenic diseases, several genes have been discovered, and genetics is now emerging as a source of information contributing not only to a better diagnosis but also to risk stratification and management of patients. The functional characterization of mutant proteins has opened new perspectives about the possibility of performing gene-specific or mutation-specific therapy. In this chapter, we will briefly summarize the genetic bases of inherited arrhythmogenic conditions and we will point out how the information derived from molecular genetics has influenced the "optimal use of traditional therapies" and has paved the way to the development of gene-specific therapy.
Priori
S G
SG
Molecular Cardiology Laboratories, IRCCS Fondazione Salvatore Maugeri, Via Ferrata 8, 27100 Pavia, Italy. spriori@fsm.it
Napolitano
C
C
Cerrone
M
M
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000235:genetics*; D017147:Defibrillators, Implantable; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels / Q000235:genetics; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000235:genetics; D008564:Membrane Potentials / Q000187:drug effects; D009154:Mutation; D062554:NAV1.5 Voltage-Gated Sodium Channel; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000235:genetics; D015222:Sodium Channels / Q000235:genetics; D013610:Tachycardia / Q000188:drug therapy / Q000235:genetics
D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D062554:NAV1.5 Voltage-Gated Sodium Channel; D019837:Ryanodine Receptor Calcium Release Channel; C568320:SCN5A protein, human; D015222:Sodium Channels